US-based regenerative medicine firm Collagen Matrix has received 510(k) clearance for a new Fibrillar Collagen Wound Dressing.

The Collagen Matrix Fibrillar Collagen Wound Dressing is an absorbent microfibrillar matrix used to treat wounds that moderately to extensively exude fluid as well as control mild bleeding.

When applied on a wound bed, the dressing begins to absorb the exudates and preserves the wound bed and fragile new tissue.

The company said that the dressing can be used for the treatment of pressure ulcers, venous stasis ulcers, diabetic ulcers, acute wounds (such as trauma and surgical wounds), and partial-thickness burns.

The approval is 40th 510(k) clearance in the firm’s history which will expand Collagen’s product offering in the advanced wound care market.

Collagen Matrix chief executive officer Shawn McCarthy said: “This 40th 510(k) milestone is a testament to our team’s tireless commitment to developing meaningful innovation in regenerative medicine throughout our 25-year history.

“We’re excited to expand our portfolio into advanced wound care, a $9B global market with numerous opportunities for our technologies to make a difference for patients worldwide.”

McCarthy added: “Significant unmet needs in this area demand more effective and proficient treatment of wounds of all types, especially chronic wounds, and with the synergies our technology platforms offer, Collagen Matrix is well-positioned to gain approvals and commercialize products quickly with our partners in markets around the world.

“With the introduction of this unique wound dressing, Collagen Matrix is demonstrating its commitment to serving the advanced wound care market.

“We have the unique ability to utilise our diverse set of technology platforms, processes, and materials to custom design products for our partners based on their needs and the problems they aim to solve with regenerative solutions.”

Over the last 25 years, the company has launched more than 75 products that have impacted the lives of more than 15 million patients worldwide.